Metis Global Partners LLC Sells 1,371 Shares of Amgen Inc. $AMGN

Metis Global Partners LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 5.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 25,725 shares of the medical research company’s stock after selling 1,371 shares during the period. Metis Global Partners LLC’s holdings in Amgen were worth $7,260,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Sequoia Financial Advisors LLC increased its position in Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after purchasing an additional 3,619 shares during the period. Atlantic Union Bankshares Corp lifted its position in shares of Amgen by 165.0% in the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after purchasing an additional 6,627 shares during the period. Davis Capital Management bought a new stake in shares of Amgen during the 3rd quarter valued at about $1,841,000. D.A. Davidson & CO. boosted its stake in shares of Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after purchasing an additional 6,222 shares in the last quarter. Finally, Global Wealth Management Investment Advisory Inc. increased its position in shares of Amgen by 56.2% during the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after buying an additional 4,699 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $366.20 on Friday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The firm has a 50 day moving average price of $336.68 and a 200-day moving average price of $313.14. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $385.12. The firm has a market capitalization of $197.19 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 3.75 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. Amgen’s dividend payout ratio is 66.90%.

Analyst Ratings Changes

AMGN has been the subject of several research analyst reports. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. Wall Street Zen lowered Amgen from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 7th. Deutsche Bank Aktiengesellschaft raised their target price on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research note on Thursday, February 5th. Guggenheim lifted their price target on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Finally, Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $354.04.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. The trade was a 30.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.76% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.